EU Pediatric Drug Rule Produces Mixed Results, Report Says
An EU regulation meant to boost pediatric drug development has led to more medicines for children since it was adopted, although actual use of new products has not increased at…
FDA Publishes Guidance for Developing Gastroesophageal Reflux Treatments in Children
The FDA issued a new draft guidance for sponsors developing treatments for gastroesophageal reflux disease in infants, children and adolescents — outlining clinical trial design considerations and the agency’s current…
Insys Founder Charged With Nationwide Conspiracy to Push Fentanyl Prescriptions
John Kapoor, founder and majority owner of Insys Therapeutics, was arrested and charged with bribery and fraud in the illegal distribution of a fentanyl spray, an opioid intended to treat…
Trump Officially Declares Opioid Epidemic a Public Health Emergency
President Donald Trump officially declared the nationwide opioid crisis a public health emergency Thursday, directing agencies to use existing authority to the best of their ability to combat the epidemic.…
The 6 Most-In-Demand Biotech Jobs Right Now
A closer look at the six jobs in life sciences that are currently in high demand. Source: BioSpace
Pfizer's $15B Consumer Health Biz May be on GlaxoSmithKline's Shopping List
Earlier this month, Pfizer's chairman and CEO, Ian Read, said he was considering selling the company's Consumer Healthcare business, or possibly spinning it off. Source: BioSpace
Top 10 Best Locations for Life Science Jobs in the World
A look at the best spots for life science jobs globally. Source: BioSpace
AbbVie Touts Late-Stage Psoriasis Drug Trial Data
AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster drug Humira or J&J's Stelara for psoriasis patients. Source: BioSpace
BlueRock Therapeutics Sets Up HQ in Cambridge, Expands Executive Team
BlueRock Therapeutics established its corporate headquarters in Cambridge, MA and has appointed two additional senior executive staffers. Source: BioSpace
FDA Calls BioMarin's Hemophilia A Drug a Breakthrough
BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation. Source: BioSpace
- Go to the previous page
- 1
- …
- 277
- 278
- 279
- 280
- 281
- 282
- 283
- …
- 610
- Go to the next page